Last reviewed · How we verify

Licorice Root

Cairo University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Licorice Root is a Small molecule drug developed by Cairo University. It is currently FDA-approved. Also known as: Glycyrrhiza Glabra.

Licorice root, also known as Glycyrrhiza glabra, is being studied in clinical trials for various conditions including Polycystic Ovary Syndrome, Irritable Bowel Syndrome, and High Caries Risk Patients. The exact mechanism of action of licorice root is currently unknown.

At a glance

Generic nameLicorice Root
Also known asGlycyrrhiza Glabra
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Licorice Root

What is Licorice Root?

Licorice Root is a Small molecule drug developed by Cairo University.

Who makes Licorice Root?

Licorice Root is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

Is Licorice Root also known as anything else?

Licorice Root is also known as Glycyrrhiza Glabra.

What development phase is Licorice Root in?

Licorice Root is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing